Glaxosmithkline Sustainability Profile
GlaxoSmithKline plc (GSK), a leading global healthcare company headquartered in Great Britain, has been at the forefront of pharmaceutical innovation since its founding in 2000, following the merger of Glaxo Wellcome and SmithKline Beecham. With a strong presence in Europe, North America, and emerging markets, GSK operates primarily in the pharmaceutical, vaccine, and consumer healthcare sectors. The company is renowned for its diverse portfolio, which includes groundbreaking medicines, vaccines, and consumer health products that address a wide range of health needs. GSK's commitment to research and development has led to significant advancements in areas such as respiratory diseases, HIV, and immunology. As a key player in the global healthcare landscape, GSK continues to achieve notable milestones, reinforcing its position as a trusted provider of innovative health solutions.
DitchCarbon Score
How does Glaxosmithkline's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Glaxosmithkline's score of 100 is higher than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Glaxosmithkline's reported carbon emissions
In 2024, GlaxoSmithKline (GSK) reported approximately 92 million kg CO2e in Scope 1 and 2 emissions in Great Britain. Globally, their emissions included about 521 million kg CO2e from Scope 1, approximately 44 million kg CO2e from Scope 2 (market-based), and a significant 8.98 billion kg CO2e from Scope 3 emissions. GSK has set ambitious climate commitments, aiming for net-zero greenhouse gas emissions across their full value chain by 2045. This includes a target of a 90% absolute reduction in emissions from a 2020 baseline across all scopes. In the near term, GSK aims to reduce absolute Scope 1 and 2 emissions by 80% by 2030 and Scope 3 emissions by 80% within the same timeframe. Notably, GSK has achieved a 6% reduction in Scope 1 and 2 emissions from 2021 levels. Their long-term strategy is aligned with the Science Based Targets initiative (SBTi), which confirms their targets are consistent with limiting global warming to 1.5°C. GSK's climate initiatives are part of a broader commitment to sustainability, reflecting their responsibility in the pharmaceutical sector to mitigate climate change impacts.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 1,040,928,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 788,149,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | 16,630,521,000 | 00,000,000,000 | 00,000,000,000 | 00,000,000,000 | 00,000,000,000 | 00,000,000,000 | - | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | - |
How Carbon Intensive is Glaxosmithkline's Industry?
How Carbon Intensive is Glaxosmithkline's Location?
Glaxosmithkline's Scope 3 Categories Breakdown
Glaxosmithkline's Scope 3 emissions, which decreased by 0% last year and decreased by approximately 46% since 2013, demonstrating supply chain emissions tracking. The vast majority of their carbon footprint comes from suppliers and value chain emissions, representing the vast majority of total emissions under the GHG Protocol, with "Use of Sold Products" being the largest emissions source at 56% of Scope 3 emissions.
Top Scope 3 Categories
Glaxosmithkline's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Glaxosmithkline has established climate goals through participation in recognized frameworks and target-setting initiatives. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
Frequently Asked Questions
Common questions about Glaxosmithkline's sustainability data and climate commitments
Let us know if this data was useful to you
Usage Policy
You're welcome to quote or reference data from this page, but please include a visible link back to this URL.
Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.